INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION
    2.
    发明公开
    INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION 审中-公开
    尿激酶和血管形成INHIBITORE

    公开(公告)号:EP1100814A2

    公开(公告)日:2001-05-23

    申请号:EP99934173.8

    申请日:1999-07-22

    IPC分类号: C07K5/062 C07K5/068 A61K38/04

    CPC分类号: C07K5/06069 A61K38/00

    摘要: Novel compounds having activity inhibitors of urokinase and in reducing or inhibiting blood vessel formation are provided. These compounds have an arginine or arginine mimic aldehyde or an arginine ketoamide group at P1. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.

    BLOOD COAGULATION PROTEIN ANTAGONISTS AND USES THEREFOR
    3.
    发明授权
    BLOOD COAGULATION PROTEIN ANTAGONISTS AND USES THEREFOR 失效
    凝血及其使用蛋白拮抗剂

    公开(公告)号:EP0554383B1

    公开(公告)日:2000-08-02

    申请号:EP91920567.4

    申请日:1991-10-17

    CPC分类号: C07K16/40 A61K38/00

    摘要: Coagulation protein antagonists are disclosed, which include monoclonal-type antibodies and related cell lines disclosed for the production of specific, neutralizing antibodies against factors VII and VIIa and the tissue factor/factor VIIa bimolecular complex, which antibodies are useful for the prevention or treatment of thrombotic and related diseases, for immunoaffinity isolation and purification of factors VII and VIIa and the tissue factor/factor VIIa complex, and for determination of factors VII or VIIa and the tissue factor/factors VII or VIIa complex in a biological sample.

    BLOOD COAGULATION PROTEIN ANTAGONISTS AND USES THEREFOR
    4.
    发明公开
    BLOOD COAGULATION PROTEIN ANTAGONISTS AND USES THEREFOR 失效
    凝血及其使用蛋白拮抗剂。

    公开(公告)号:EP0554383A1

    公开(公告)日:1993-08-11

    申请号:EP91920567.0

    申请日:1991-10-17

    CPC分类号: C07K16/40 A61K38/00

    摘要: Les antagonistes de protéine de coagulation comprennent des anticorps monoclonaux et des lignées cellulaires apparentées pour la production d'anticorps spécifiques de neutralisation contre des facteurs VII et VIIa et le complexe bi-moléculaire facteur tissulaire/facteur VIIa, ces anticorps étant utiles à la prévention ou au traitement de maladies thrombotiques et autres maladies du même genre, à l'isolement par immunoaffinité et à la purification de facteurs VII et VIIa et du complexe facteur tissulaire/facteur VIIa, ainsi qu'à la détermination de facteurs VII ou VIIa et du complexe facteur tissulaire/facteurs VII ou VIIa dans un échantillon biologique.